GL1X · GenesisL1 explorer

MolNFT v2 · #10642 · protein

Crystal Structure of the K intermediate of bacteriorhodopsin

1IXF: “Crystal Structure of the K intermediate of bacteriorhodopsin”. X-ray diffraction at 2.6, 6 ligands (L3P, RET, L2P), 1 pocket (best druggability 0.80). MolNFT v2 #10642 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
1IXF
Type
protein
Length
227 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v2 / PDB Bank
Contract
0xd58B01f6C18086e5202cdC5D7Ad3E41790360102
Owner
0xF4e1AA6f26B7DA48EeAD9B24a97927303eeA07b8
Resolution
2.6
Source
Halobacterium salinarum
Molecule
bacteriorhodopsin
UniProt
P02945
Ligands
L3P, RET, L2P, GLC, MAN, GAL
Pockets
1 · best druggability 0.80

Structure

x-ray diffraction · resolution 2.6 · 1 distinct chain · 75% helix, 4% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
Abacteriorhodopsinprotein22775% helix, 4% strandP02945

Ligands and binding sites

  • L3P · 2,3-di-O-phytanly-3-sn-glycero-1-phosphoryl-3'-sn-glycerol-1'-phosphate · ligand · 4 copies · chains A
  • RET · Retinal · ligand · chains A
  • L2P · 2,3-di-phytanyl-glycerol · ligand · chains A
  • GLC · alpha-D-glucopyranose · sugar · chains A
  • MAN · alpha-D-mannopyranose · sugar · chains A
  • GAL · beta-D-galactopyranose · sugar

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11350.800.9726RET

Modifications

Observed in the structure: 1 cofactor (retinal Schiff base).

Compared structures

  • 1IXF · Crystal structure of the K intermediate of bacteriorhodopsin · the same entry in another collection · chain A against A, TM-score 1.00
  • P02945 · AlphaFold monomer V2.0 prediction for bacteriorhodopsin (P02945) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.